Intellia Therapeutics Announces Closing of Initial Public Offering
12 May 2016 - 6:05AM
Intellia Therapeutics, Inc. (NASDAQ:NTLA) today announced the
closing of its initial public offering of 6,900,000 shares of its
common stock at an initial public offering price of $18.00 per
share, which includes the exercise in full by the underwriters of
their option to purchase up to 900,000 additional shares of common
stock. Shares began trading on the NASDAQ Global Market on May 6,
2016.
Credit Suisse, Jefferies LLC and Leerink Partners
acted as joint book-running managers for the offering.
Wedbush PacGrow acted as lead manager.
The net proceeds of the offering to Intellia were
approximately $112.9 million, after deducting underwriting
discounts and commissions and estimated offering expenses.
A registration statement relating to these securities was
declared effective by the Securities and Exchange Commission on May
5, 2016. Copies of the final prospectus related to the offering may
be obtained from: Credit Suisse Securities (USA) LLC, Attn:
Prospectus Dept., One Madison Avenue, New York, NY 10010, by
telephone at (800) 221-1037 or by email at
newyork.prospectus@credit-suisse.com; Jefferies LLC, Attn: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New
York, NY 10022, by telephone at 877-547-6340 or by email at
Prospectus_Department@Jefferies.com; or Leerink Partners LLC, Attn:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA
02110, by telephone at 800-808-7525 ext. 6142 or by email
at Syndicate@Leerink.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Intellia Therapeutics
Intellia Therapeutics is a leading gene editing company focused
on the development of proprietary products utilizing the recently
developed biological tool, CRISPR/Cas9.
Contacts:
Jennifer Mound Smoter
Chief External Affairs & Communications Officer
+1 224-804-4462
jenn.smoter@intelliatx.com
John Graziano
Trout Group
646- 378-2942
Chad Rubin
Trout Group
646 378-2947
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jul 2023 to Jul 2024